These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 30805685)

  • 1. Prognostic impact of non-adherence to follow-up cystoscopy in non-muscle-invasive bladder cancer (NMIBC).
    Datovo JCF; Neto WA; Mendonça GB; Andrade DL; Reis LO
    World J Urol; 2019 Oct; 37(10):2067-2071. PubMed ID: 30805685
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations.
    Kassouf W; Traboulsi SL; Schmitz-Dräger B; Palou J; Witjes JA; van Rhijn BW; Grossman HB; Kiemeney LA; Goebell PJ; Kamat AM
    Urol Oncol; 2016 Oct; 34(10):460-8. PubMed ID: 27368880
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of frequent cystoscopy on surgical care and cancer outcomes among patients with low-risk, non-muscle-invasive bladder cancer.
    Schroeck FR; Lynch KE; Li Z; MacKenzie TA; Han DS; Seigne JD; Robertson DJ; Sirovich B; Goodney PP
    Cancer; 2019 Sep; 125(18):3147-3154. PubMed ID: 31120559
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of the intensity of follow-up cystoscopy in patients with high-risk non-muscle-invasive bladder cancer.
    Miyake M; Nishimura N; Nishioka Y; Fujii T; Oda Y; Miyamoto T; Tomizawa M; Shimizu T; Owari T; Ohnishi K; Hori S; Morizawa Y; Gotoh D; Nakai Y; Torimoto K; Tanaka N; Imamura T; Fujimoto K
    Int Urol Nephrol; 2024 Mar; 56(3):827-837. PubMed ID: 37910382
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment changes and long-term recurrence rates after hexaminolevulinate (HAL) fluorescence cystoscopy: does it really make a difference in patients with non-muscle-invasive bladder cancer (NMIBC)?
    Geavlete B; Multescu R; Georgescu D; Jecu M; Stanescu F; Geavlete P
    BJU Int; 2012 Feb; 109(4):549-56. PubMed ID: 21711438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal timing for the first cystoscopic follow-up using time-to-treatment initiation analysis of oncologic outcomes in primary non-muscle invasive bladder cancer.
    Kim JS; Lee J; Nguyen TT; Choi SY
    Sci Rep; 2024 Apr; 14(1):8440. PubMed ID: 38600160
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing recurrence in non-muscle-invasive bladder cancer by systematically implementing guideline-based recommendations: effect of a prospective intervention in primary bladder cancer patients.
    Sörenby A; Baseckas G; Bendahl PO; Brändstedt J; Håkansson U; Nilsson S; Patschan O; Tinzl M; Wokander M; Liedberg F; Gudjonsson S
    Scand J Urol; 2019; 53(2-3):109-115. PubMed ID: 31064253
    [No Abstract]   [Full Text] [Related]  

  • 9. Oncological outcomes of a single but extensive transurethral resection followed by appropriate intra-vesical instillation therapy for newly diagnosed non-muscle-invasive bladder cancer.
    Koie T; Ohyama C; Hosogoe S; Yamamoto H; Imai A; Hatakeyama S; Yoneyama T; Hashimoto Y; Yoneyama T; Tobisawa Y; Mori K
    Int Urol Nephrol; 2015 Sep; 47(9):1509-14. PubMed ID: 26149637
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Presence of Concomitant Non-muscle-invasive Bladder Cancer in Chinese Patients with Upper Tract Urothelial Carcinoma: Risk Factors, Characteristics, and Predictive Value.
    Fang D; Zhang L; Li X; Yu W; Singla N; Zhao G; Xiong G; Song Y; He Q; He Z; Zhou L
    Ann Surg Oncol; 2015 Aug; 22(8):2789-98. PubMed ID: 25564161
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer.
    Ferro M; Vartolomei MD; Russo GI; Cantiello F; Farhan ARA; Terracciano D; Cimmino A; Di Stasi S; Musi G; Hurle R; Serretta V; Busetto GM; De Berardinis E; Cioffi A; Perdonà S; Borghesi M; Schiavina R; Cozzi G; Almeida GL; Bove P; Lima E; Grimaldi G; Matei DV; Crisan N; Muto M; Verze P; Battaglia M; Guazzoni G; Autorino R; Morgia G; Damiano R; de Cobelli O; Shariat S; Mirone V; Lucarelli G
    World J Urol; 2019 Mar; 37(3):507-514. PubMed ID: 29992381
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Results of a prospective randomized study assessing the efficacy of fluorescent cystoscopy-assisted transurethral resection and single instillation of doxorubicin in patients with non-muscle-invasive bladder cancer.
    Rolevich AI; Zhegalik AG; Mokhort AA; Minich AA; Vasilevich VY; Polyakov SL; Krasny SA; Sukonko OG
    World J Urol; 2017 May; 35(5):745-752. PubMed ID: 27604374
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intravesical BCG treatment causes a long-lasting reduction of recurrence and progression in patients with high-risk non-muscle-invasive bladder cancer.
    Thiel T; Ryk C; Renström-Koskela L; Steineck G; Schumacher MC; Wiklund NP; de Verdier PJ
    World J Urol; 2019 Jan; 37(1):155-163. PubMed ID: 29905887
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic relevance of positive urine markers in patients with negative cystoscopy during surveillance of bladder cancer.
    Todenhöfer T; Hennenlotter J; Guttenberg P; Mohrhardt S; Kuehs U; Esser M; Aufderklamm S; Bier S; Harland N; Rausch S; Gakis G; Stenzl A; Schwentner C
    BMC Cancer; 2015 Mar; 15():155. PubMed ID: 25884545
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Cystoscopy in non-muscle-invasive bladder cancer: when and how (rigid or flexible)].
    Cicione A; Cantiello F; Damiano R
    Urologia; 2013; 80 Suppl 21():11-5. PubMed ID: 23559127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up in non-muscle invasive bladder cancer: facts and future.
    Witjes JA
    World J Urol; 2021 Nov; 39(11):4047-4053. PubMed ID: 33367941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and cost effectiveness of hexaminolevulinate-guided blue-light cystoscopy: evidence review and updated expert recommendations.
    Witjes JA; Babjuk M; Gontero P; Jacqmin D; Karl A; Kruck S; Mariappan P; Palou Redorta J; Stenzl A; van Velthoven R; Zaak D
    Eur Urol; 2014 Nov; 66(5):863-71. PubMed ID: 25001887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic diagnosis of non-muscle-invasive bladder cancer with hexaminolevulinate cystoscopy: a meta-analysis of detection and recurrence based on raw data.
    Burger M; Grossman HB; Droller M; Schmidbauer J; Hermann G; Drăgoescu O; Ray E; Fradet Y; Karl A; Burgués JP; Witjes JA; Stenzl A; Jichlinski P; Jocham D
    Eur Urol; 2013 Nov; 64(5):846-54. PubMed ID: 23602406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of smoking status and recurrence of non-muscle invasive bladder cancer among patients managed with blue light cystoscopy.
    Matulewicz RS; Ravvaz K; Weissert JA; Porten S; Steinberg GD;
    Urol Oncol; 2021 Dec; 39(12):833.e19-833.e26. PubMed ID: 34053856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.